Phaseline

Companies › City Therapeutics

City Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Ophthalmology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CITY-RBP4
siRNA targeting RBP4
RBP4Phase 1Stargardt Disease 1Feb 2028
CITY-FXI
siRNA targeting Factor XI
FXIPhase 1Factor V LeidenMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07836452CITY-RBP4Phase 1Stargardt Disease 1OphthalmologyFeb 2028
NCT07430397CITY-FXIPhase 1Factor V LeidenCardiovascularMar 2028

From the company's SEC filings

Press releases filed as 8-K in the last year:

Targets

FXI (1) RBP4 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.